Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects.
Adolescence is a critical phase of active brain development often characterized by the initiation of marijuana (Cannabis sativa) use. Limited information is known regarding the endogenous cannabinoid system of the adolescent brain as well as related neurotransmitters that appear sensitive to cannabis exposure. We recently observed that adult rats pre-exposed to Delta-9-tetrahydrocannabinol (THC) during adolescence self-administered higher amounts of heroin and had selective impairments of the enkephalin opioid system within the nucleus accumbens (NAc) implicated in reward-related behavior. To explore the ontogeny of the cannabinoid and opioid neuronal systems in association with adolescence THC exposure, rats were examined at different adolescent stages during an intermittent THC paradigm (1.5 mg/kg i.p. every third day) from postnatal days (PNDs) 28-49. Rat brains were examined 24 h after injection at PND 29 (early adolescence), PND 38 (mid adolescence) and PND 50 (late adolescence) and analyzed for endocannabinoids (anandamide and 2-arachidonoylglycerol), Met-enkephalin, cannabinoid CB(1) receptors and micro opioid receptors (microOR) in the NAc, caudate-putamen and prefrontal cortex (PFC). Of the markers studied, the endocannabinoid levels had the most robust alterations throughout adolescence and were specific to the PFC and NAc. Normal correlations between anandamide and 2-arachidonoylglycerol concentrations in the NAc (positive) and PFC (negative) were reversed by THC. Other significant THC-induced effects were confined to the NAc - increased anandamide, decreased Met-enkephalin and decreased microORs. These findings emphasize the dynamic nature of the mesocorticolimbic endocannabinoid system during adolescence and the selective mesocorticolimbic disturbance as a consequence of adolescent cannabis exposure.
Ellgren
M
M
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Artmann
A
A
Tkalych
O
O
Gupta
A
A
Hansen
H S
HS
Hansen
S H
SH
Devi
L A
LA
Hurd
Y L
YL
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000254:growth & development* / Q000502:physiology*; D002851:Chromatography, High Pressure Liquid; D013759:Dronabinol / Q000494:pharmacology*; D063388:Endocannabinoids; D004744:Enkephalin, Methionine / Q000378:metabolism; D005989:Glycerides / Q000378:metabolism; D008032:Limbic System / Q000187:drug effects / Q000254:growth & development* / Q000502:physiology*; D008297:Male; D013058:Mass Spectrometry; D017072:Neostriatum / Q000254:growth & development / Q000378:metabolism; D009434:Neural Pathways / Q000254:growth & development / Q000378:metabolism; D009714:Nucleus Accumbens / Q000254:growth & development / Q000378:metabolism; D018847:Opioid Peptides / Q000502:physiology*; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D017397:Prefrontal Cortex / Q000254:growth & development / Q000378:metabolism; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011863:Radioimmunoassay; D051381:Rats; D020318:Rats, Long-Evans; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects / Q000502:physiology; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000502:physiology
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D005989:Glycerides; D018847:Opioid Peptides; D053284:Polyunsaturated Alkamides; D011619:Psychotropic Drugs; D043884:Receptor, Cannabinoid, CB1; D017450:Receptors, Opioid, mu; D004744:Enkephalin, Methionine; D013759:Dronabinol; C094503:glyceryl 2-arachidonate; C078814:anandamide